DOI: https://doi.org/10.53350/pjmhs22165422

ORIGINAL ARTICLE

Patient Adherence and Elimination of Helicobacter Pylori Infection with Once-Daily Triple Therapy Versus Traditional Triple Therapy: A longitudinal study

NADEEM[1], NAZEER AHMED[2], HYDER WAJID ABBASI[3], KHADIM HUSSAIN SAMEJO[4], MOHSIN ALI[5], SHEIKH MUHAMMAD TAQQI ANWAR[6]

[1]*Assistant Professor Gastroenterology, Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences Gambat Pakistan*
[2]*Senior Registrar Gastroenterology and Hepatolgy, Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences Gambat Pakistan*
[3]*Senior Registrar Gastroenterology, Pakistan Institute of Medical Sciences Islamabad Pakistan*
[4]*Senior Registrar Gastroenterology, Asian Institute of Medical Science Hyderabad Pakistan*
[5]*Consultant Gastroenterologist Gastroenterology, Peoples University of Medical and Health Sciences Hospital Nawabshah Pakistan*
[6]*Senior Registrar Gastroenterology and Hepatology, Poonch Medical College Rawalakot AJK Pakistan*
Corresponding author: Nadeem, Email: nadimbajkani@gmail.com

ABSTRACT

Aim: To assess the patient Adherence and Elimination of Helicobacter pylori Infection with Once-Daily Triple Therapy versus Traditional Triple Therapy

Study design: A longitudinal study

Place and Duration: This study was conducted at Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences Gambat Pakistan from Faburay 2020 to February 2021.

Methodology: A total of 159 patients with aggressive peptic ulcer disease were checked positive for rapid urease exam or 13C-UBT had been provided either once-daily (Tinidazole 1000 milligrams + Azithromycin 500 milligrams +Rabeprazole 40 milligrams) or twice-daily (Amoxicillin 1000 milligrams +Clarithromycin 500 milligrams +Esomeprazole 40). The fast urease exams with 13C-UBT were performed ten weeks following the end of the medication. Pill counting, standardized surveys, and interviews were used to assess compliance and side effects.

Results: When compared to the twice-daily cohort, patient adherence was shown to be higher in the once-daily cohort (84.8 percent) (68.8 percent) respectively. Meanwhile, 74.6 percent of the participants tested negative for H. pylori following therapy with the once-daily prescription and reported symptomatic improvement. The standard regime, on the other hand, resulted in 68.7% of the individuals testing negative to UBT and symptomatic alleviation (p=0.4063).

Conclusion: No statistically substantial variation in elimination frequencies between the two regimes was observed. The once-daily prescription, on the other hand, had improved drug adherence than the standard treatment plan, indicating that it could be a secure and a superior tolerated substitute to traditional triple treatments, particularly for patients who do not adhere to the regimen. To corroborate the findings, more research should be done.

Keywords: peptic ulcer disease, adults, helicobacter pylori, azithromycin

INTRODUCTION

Infection with Helicobacter pylori is a widespread, typically permanent condition that can be detected all over the world. [1] As per investigations, contamination rates vary by geographical area, but the proportion of affected individuals has remained stable or even risen over the last 30 years owing to demographic expansion and re-infection as a result of failed elimination efforts. [2] Since it is linked with greater overcrowded living situations that favor intrafamilial transfer, a lower economical position is a hazard variable for H. pylori infection. [3] Iatrogenic disease caused by endoscopes is also a possibility. [4]

On an 'intention-to-treat' premise, the suggested first-line therapy treatments should yield a Helicobacter pylori eradication percentage of greater than 80%, as per the Maastricht agreement. [5] Furthermore, according to multiple large medical studies and Meta-analyses, the most frequently employed first-line triple treatment might not affect over 20% of individuals. [6-8] A variety of researches have looked into the effectiveness of mixing levofloxacin medicines as a first-line H. pylori elimination treatment. [9-12]

Two antibiotics plus a proton pump inhibitor (PPI) are commonly used as first-line treatment for H. pylori elimination for a duration of 10 - 14 days. [13] In-vitro resistance screening and personalized therapy methods depending on MIC are challenging to execute in practice because of the increase in prices and longer duration of treatment. As a result, many consensual organizations around the world accept multimodal regimes as the normal course of action.

In the last ten years, main and secondary tolerance to medicines such as clarithromycin, metronidazole, or levofloxacin has achieved alarming proportions in various countries, rendering their incorporation in first-line regimens challenging.

Adherence is a multifaceted procedure that is closely linked to elimination effectiveness and, by extension, antibiotic sensitivity. According to past studies, 10% of individuals who are given H. pylori elimination treatment were neglected to follow merely 60% of the drugs. Individuals on treatment must take around 6 tablets daily, totaling 60 tablets during the course of therapy. Individuals are frequently driven to become non-compliant owing to the intricacy of therapy as well as the bad impacts associated with drugs like acidity. A once-daily prescription could possibly enhance patient adherence by simplifying therapy and lowering costs. Long dosage gaps paired with greater dosages, as demonstrated by in-vitro investigations, may also help to avoid antibiotic sensitivity. [14]

The goal of this study was to develop an easy routine to improve compliance with efficacious drugs that can be administered at extended dosage periods and can be used as the first-line treatment for H. pylori elimination.

METHODOLOGY

This study looked at 159 dyspeptic individuals who were 18 years or older and had not used antibiotics, PPIs, NSAIDs, or steroids in the previous four weeks and was scheduled to have an esophagogastroduodenoscopy (EGD). Individuals with poor liver functioning, aberrant renal operation, cancer, and pregnancy or breastfeeding females were excluded from the study. Individuals with pyloric stenosis or a leaking ulcer were also excluded from the study. Every participant who agreed to participate signed the written approval. Permission was taken from the ethical review committee of the institute.

Individuals who met the eligibility requirements and were diagnosed on the basis of RUT or 13C-UBT were assigned to either of two therapy routines: Twice every day (BD): Amoxicillin 1000 milligrams, Clarithromycin 500 milligrams, Esomeprazole 40

milligrams for 10 days, or Once every day: Azithromycin 500 milligrams for 7 days, Tinidazole 1000 milligrams, Rabeprazole 40 milligrams for 10 days.

Adherence was measured utilizing a pill number, MMAS-8 rating, and an interview session at the conclusion of the 10-day therapy session. Following 10 weeks of medication-free time, the individuals were contacted for a follow-up appointment. Following 10 weeks, every participant had an EGD plus a Rapid Urease Test (RUT) or a 13C-UBT. Negative findings 10 weeks following therapy were considered as elimination therapy effectiveness.

Following 10 weeks of medication, the key medical result assessment was the elimination of H. pylori bacterium as shown by a null RUT or 13C-UBT. The Morisky Medication Adherence Scale and collecting tablets at the conclusion of the treatment were used to assess adherence. Excellent adherence was described as taking over 90% of the recommended medications as determined by an assessment during the follow-up appointment once the therapy was completed. At the discussion, the causes for poor compliance and unpleasant medication treatment events were also determined and documented.

With a strength of 85 percent and a significant threshold of 0.05, we calculated the sample group required to identify an 8 percent variation in adherence rate comparing the once-daily triple treatment category and the usual triple therapy category. The total sample size for every cohort was 74, with an impact size of 0.5, based on the results of the pilot research.

The demographic characteristics, foundation, and medical features of the research population were analyzed using comprehensive statistics. Proportions were used to indicate result factors. Ongoing variables are presented as figures and %, ANOVA is used to evaluate them. All the data were analyzed by using SPSS version 23.

RESULTS

The average age of the patients was 39.52 13.6 years. The socioeconomic features of the population are shown in Table 1. Hypothyroidism, on the other hand, was much more prevalent in subgroup OD. A literature study was conducted to learn more about the link between hypothyroidism and H. pylori disease. Thyroid concentrations and the prevalence of H. pylori are linked in several studies; however, none of them include hypothyroidism as a factor in the elimination frequency. Three participants were abandoned to follow-up in the once-daily treatment cohort, out of a total of 83. Likewise, two participants were abandoned to follow-up in the twice-daily (standard) treatment cohort out of 83.

Adverse effects did not cause any patients to stop taking their medication. Table 1 shows the results of the initial endoscopy. Gastritis was found in 83 percent of individual cohort OD and 78 percent of individuals in cohort BD. In the OD category, 11% of individuals had duodenal or stomach ulcers, while in the BD cohort, 13% had duodenal and otherwise gastric ulcers. Endoscopy was found to be regular in 7% of category OD participants and 9% of category BD individuals (Table 2).

According to ITT assessment, the OD cohort had a 75.7 percent elimination rate and the BD group had a 67.8% elimination rate; among individuals with strong adherence, the OD cohort had a 75.6 percent elimination rate and the BD group had a 76.3 percent elimination rate.

Dysguesia was the greatest prevalent negative effect in both categories, with 46.9% of individuals in cohort OD and 53 percent of participants in cohort BD experiencing it (As shown in Table 3). The incidence rates of adverse outcomes were equivalent in the once-daily as well as twice-daily groups. All of the adverse reactions were minor, and no participant left the trial as a result of them.

At the completion of the treatment, adherence was measured by measuring pills. Patients who took 80% of their prescriptions or more were regarded to be in "excellent adherence." According to interviews conducted at the completion of the treatment, 85 percent of individuals in cohort OD and 68 percent of participants in class BD exhibited strong adherence. Furthermore, participants in the OD group had considerably higher adherence than those in the BD category, as measured by the MMAS-8 survey (As shown in Table 3).

At the conclusion of the therapy, both categories demonstrated substantial improvements in all indicators. Heartburn were reduced more in cohort OD (82.3 percent and 80 percent, correspondingly) than in group BD (64.6 percent and 76 percent, respectively) between the categories (As shown in Table 4).

Table 1: Participants demographics, baseline, and medical characteristics

Variables		Group 1 (n=78)	Group 2 (n=81)	P value
Age		39.52 ± 13.49	39.78 ± 14.0	0.888
Gender	Male	37 (47)	35 (44)	0.694
	Female	42 (52.9)	45 (56)	
	Smoking	6 (7.86)	6 (7.75)	0.981
	Alcohol consumption	1 (1.5)	4 (4.75)	1.000
Risk factors	Consumption of coffee or tea	50 (63.0)	40 (50.25)	0.171
	Mixed diet	74 (93.9)	78 (97.2)	0.718
	NSAID use	3 (3.5)	2 (2.75)	0.680
Co-morbidities	Hypertension	19 (24.3)	13 (16.2)	0.104
	Diabetes Mellitus	12 (14.9)	7 (9.1)	0.447
	Hypothyroidism	10 (12.9)	3 (3.5)	0.008
	Gastritis	66 (83.3)	62 (77.6)	0.778
	Reflux esophagitis	5 (6.6)	7 (8.5)	
	ulcer	9 (11.1)	10 (12.75)	

Table 2: Complaints at the start of therapy in each category of participants

Signs at start	Group I	Group II	P value
Heartburn	49	34	0.015
Belching	45	32	0.033
Bloating	50	46	0.458
Fatty diet sensitivity	9	15	0.220
Nausea/sickness	20	13	0.138
Abdominal pain	41	40	0.808
Lethargy	40	54	0.032
SOB	34	23	0.061

Table 3: Side effects and Adherence of treatment

Side effects	Group I	Group II	P value
Dizziness	6	6	1.000
Nausea/sickness/vomit	2	4	0.494
Headaches	8	3	0.099
Rashes	3	3	1.000
Dysguesia	31	31	0.950
Dry mouth	0	3	0.121

Table 4: Changes in symptom ratings in the 2 categories.

Signs	Group I % change	P value	Group II % change	P value	P value between cohorts
Dizziness	-82.33%	<0.001	-62.64%	<0.001	0.001
Nausea/sickness/vomit	-77.09%	<0.001	-73.73%	<0.001	0.068
Headaches	-76.51%	<0.001	-72.33%	<0.001	0.062
Rashes	-89.99%	<0.001	-76.00%	<0.001	0.678
Dysguesia	-79.95%	<0.001	-49.99%	<0.001	0.335
Dry mouth	-82.33%	<0.001	-76.61%	<0.001	0.382
Dizziness	-80.49%	<0.001	-83.91%	<0.001	0.195
Nausea/sickness/vomit	-79.99%	<0.001	-76.00%	<0.001	0.465

DISCUSSION

H. pylori infects over 50% of the globe's inhabitants, with different levels of incidence across areas. [15] As per the ISG, most recent consensus findings, there has been an upsurge in burden of disease and a high incidence rate of H. pylori in India during the last 10 years. [16] Moreover, a reasonable correlation has been found regarding a decrease in stomach cancer-related death and a general increase in appropriate elimination rates in East Asian nations. [17]

H. pylori has become resistant to various H. pylori elimination treatments due to the processes through which it has evolved to persist in the stomach. As a result, multidrug treatments with two antibiotics as well as a PPI are used to treat it, with varying time periods, strengths, and dosages. [18] The frequency of elimination is influenced by a variety of individual variables, with the existence of stomach ulcers and a shortage of drug adherence being negatively related [19]. Poor compliance invariably results in sub therapeutic amounts or suboptimal doses, which in turn contributes to poor health outcomes and a lower elimination rate. The most significant factor affecting cure rates, aside from individual and environmental factors, is H. influenza drug sensitivity pylori strains, which are growing year after year.

Levofloxacin possesses a half-life of 8–16 hours and is primarily excreted by the kidneys. It can be taken once a day. It has few combinations with other medications and has a minimal rate of negative impacts. [20, 21]

Based on a previous study analyzing H. pylori antimicrobial resistance, 81.4 percent of all H. pylori isolates in India were sensitive to metronidazole, 53.9 percent were sensitive to levofloxacin, and 21.4 percent were sensitive to Clarithromycin. Besides that, multidrug sensitivity was observed in 58.3% of overall isolated strains, with 86.6 percent resilient to at least both metronidazole as well as levofloxacin, implying elevated primary sensitivity to metronidazole and levofloxacin & moderate opposition to Clarithromycin, limiting their utility as first-line therapy.

A once-daily anti-H. Pylori treatment was tested and assessed with a twice-daily H. pylori treatment in this study. To select medicines for a once-daily treatment, researchers looked at half-lives and tissue concentrations of a variety of medicines. Prior trials in other nations incorporated levofloxacin in their once-daily prescription, which we excluded due to the antibiotic's high consumption rate in our country.

Tinidazole, a nitroimidazole-class medication, was used in our study. When tried to compare to parenteral delivery, nitroimidazoles achieve a very large quantity in the gastric lumen (up to 1000 milligrams) and have an oral bioavailability of more than 90%. Tinidazole possesses a half-life of 11 to 13 hours and has been demonstrated to be effective in earlier research. Tinidazole action is not affected by pH. In addition, compared to metronidazole, the medication has improved tolerance and pharmacokinetics.

The once-daily prescription in our trial consisted of a mixture of Azithromycin & Tinidazole, as well as a PPI. Once a sub-analysis of individuals with good adherence in both categories was undertaken, the elimination rate in both categories improved. However, there was no statistically substantial variation in the elimination rate between the cohorts. Drug adherence among individuals was influenced by a variety of parameters, notably the length of therapy, the number of pharmaceuticals prescribed, and drug adverse effects.

We recognize that this study has shortcomings. The elimination rate for first-line treatment with either prescription did not meet the desired elimination percentage of 90%. It was difficult to blind the participants in the experiment because of the circumstances. Self-reported compliance and negative occurrence assessment interviews have flaws such as social acceptability prejudice and an overestimation of compliance. Despite the fact that measurements such as the tablet count technique were utilized, they can often mislead compliance because they do not assess whether the prescription was taken promptly.

Because a symptom evaluation scale could not be employed in our research, we had to rely on the number of patients. We required dividing individuals into "symptom observed" and "symptom not observed" groups for data analysis of symptom evaluation; nevertheless, this resulted in oversimplification and the lack of data about symptom intensity.

CONCLUSION

Once tried to compare to the twice-daily treatment, the once-daily prescription did not produce a statistically meaningful elimination rate. A once-daily routine, on the other hand, led to improved treatment adherence than the traditional schedule. The once-daily medication is harmless and effective, and it appears to be a well-tolerated substitute to traditional triple therapy, particularly for non-compliant patients. To corroborate the findings, more research should be done.

Funding source: None

Conflict of interest: None

Permission: Permission was taken from the ethical review committee of the institute

REFERENCES

1. Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VW, Wu JC, Chan FK. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017 Aug 1; 153(2):420-9.
2. Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Alimentary pharmacology & therapeutics. 2017 Nov; 46(9):773-9.
3. Bamford KB, Bickley J, Collins JS, Johnston BT, Potts S, Boston V, Owen RJ, Sloan JM. Helicobacter pylori: comparison of DNA fingerprints provides evidence for intrafamilial infection. Gut. 1993 Oct 1; 34(10):1348-50.
4. Langenberg W, Rauws EA, Oudbier JH, Tytgat GN. Patient-to-patient transmission of Campylobacter pylori infection by fiberoptic gastroduodenoscopy and biopsy. Journal of Infectious Diseases. 1990 Mar 1; 161(3):507-11.
5. Malfertheiner P, Megraud F, O'morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection—The Maastricht 2-2000 Consensus Report. Alimentary pharmacology & therapeutics. 2002 Feb 20; 16(2):167-80.
6. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists—their efficacy with antibiotics in Helicobacter pylori eradication. Alimentary pharmacology & therapeutics. 2003 Oct; 18(8):757-66.
7. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP, Hp Study Group of the Asociación Española de Gastroenterología. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Official journal of the American College of Gastroenterology| ACG. 2005 Aug 1; 100(8):1696-701.
8. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gurnari M, Caracciolo F, Zippi M, Pica R. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter. 2006 Dec; 11(6):562-8.
9. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Alimentary pharmacology & therapeutics. 2000 Oct; 14(10):1339-43.
10. Di Caro S, Zocco MA, Cremonini F, Candelli M, Nista EC, Bartolozzi F, Armuzzi A, Cammarota G, Santarelli L, Gasbarrini A. Levofloxacin based regimens for the eradication of Helicobacter pylori. European journal of gastroenterology & hepatology. 2002 Dec 1; 14(12):1309-12.
11. Cammarota G, Cianci R, Cannizzaro O, Martino A, Fedeli P, Lecca PG, di Caro S, Cesaro P, Branca G, Gasbarrini G. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. Journal of clinical gastroenterology. 2004 Feb 1; 38(2):110-4.

12. Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, Rivera M, Palladini D, Nardi F, Paoluzi P. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to standard therapy for Helicobacter pylori eradication. Digestive and liver disease. 2005 Aug 1; 37(8):571-6.
13. Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future microbiology. 2010 Apr; 5(4):639-48.
14. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, Bouvenot G, Eschwége E. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. Jama. 1998 Feb 4; 279(5):365-70.
15. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Alimentary pharmacology & therapeutics. 2002 Mar; 16:3-15.
16. Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian Journal of Gastroenterology. 2021 Aug; 40(4):420-44.
17. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Cancer epidemiology. 2009:467-77.
18. Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.
19. Björkholm B, Falk P, Engstrand L, Nyren O. Helicobacter pylori: the resurrection of the cancer link. Journal of internal medicine. 2003 Feb; 253(2):102-19.
20. Sprandel KA, Rocivold KA. Safety and tolerability of fluoroquinolones. Clinical Cornerstone. 2003 Jan 1; 5:S29-36.
21. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs. 1999 Oct; 58(2):65-70.